Coherus BioSciences, Inc.

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Vexler Vladimir

(Last)

(First)

(Middle)

COHERUS BIOSCIENCES, INC.

333 TWIN DOLPHIN DRIVE, SUITE 600

(Street)

REDWOOD CITY

94065

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/16/2018

3. Issuer Name and Ticker or Trading Symbol
Coherus BioSciences, Inc. [ CHRS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, $0.0001 par value	12,300	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	02/28/2023	Common Stock	71,982	2.0838	D
Stock Option (right to buy)	⁽²⁾	04/01/2025	Common Stock	25,000	29	D
Stock Option (right to buy)	⁽³⁾	02/26/2026	Common Stock	25,000	14.43	D
Stock Option (right to buy)	⁽⁴⁾	05/11/2026	Common Stock	24,618	17.17	D
Stock Option (right to buy)	⁽⁵⁾	04/03/2027	Common Stock	25,000	20.15	D
Stock Option (right to buy)	⁽⁶⁾	08/06/2027	Common Stock	50,000	12.7	D
Stock Option (right to buy)	⁽⁷⁾	11/15/2027	Common Stock	25,000	9.3	D
Stock Option (right to buy)	⁽⁸⁾	02/01/2028	Common Stock	75,000	10.05	D

Explanation of Responses:

1. The original grant was for 86,982 shares, of which 15,000 shares have been exercised and sold. The remaining shares underlying this option are fully vested and exercisable as of the date hereof.

2. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from April 1, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

3. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from March 1, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

4. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from May 6, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

5. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from April 3, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

6. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The underlying shares subject to the option vest and become exercisable over two years as follows: Fifty percent (50%) of the underlying shares subject to the option vest and become exercisable on August 1, 2018, an additional twenty-five percent (25%) of the underlying shares subject to the option vest and become exercisable on February 1, 2019 and twenty-five percent (25%) of the underlying shares subject to the option vest and become exercisable on August 1, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

7. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from November 15, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

8. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Remarks:

	/s/ Jean Frederic Viret, as Attorney-in-Fact for Vladimir Vexler	11/20/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

                               POWER OF ATTORNEY

     KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and
appoints each of (i) the Chief Financial Officer of Coherus BioSciences, Inc.,a

Delaware corporation (the "Company"), who is currently Jean-Frederic Viret,
Ph.D., (ii) the Company's Senior Vice President, Legal Affairs and General
Counsel, who is currently Matthew R. Hooper and (iii) the Company's Controller,
who is currently Lurette Lau, and their respective successors, signing singly,
with full power of substitution, as the undersigned's true and lawful attorney-
in-fact to:

     (1)  execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer or director of the Company, Forms 3, 4 and 5 (including
amendments thereto) in accordance with Section 16(a) of the Securities Exchange
Act of 1934 and the rules and regulations thereunder and a Form ID, Uniform
Application for Access Codes to File on EDGAR;

     (2)  do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Forms 3, 4
or 5 or Form ID and timely file such forms (including amendments thereto) and
application with the United States Securities and Exchange Commission and any
stock exchange or similar authority; and

     (3)  take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

     The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.

     The undersigned agrees that each such attorney-in-fact herein may rely
entirely on information furnished orally or in writing by the undersigned to
such attorney-in-fact.  The undersigned also agrees to indemnify and hold
harmless the Company and each such attorney-in-fact against any losses, claims,
damages or liabilities (or actions in these respects) that arise out of or are
based upon any untrue statements or omission of necessary facts in the
information provided by the undersigned to such attorney-in fact for purposes of
executing, acknowledging, delivering or filing Forms 3, 4 or 5 (including
amendments thereto) or Form ID and agrees to reimburse the Company and such
attorney-in-fact for any legal or other expenses reasonably incurred in
connection with investigating or defending against any such loss, claim, damage,
liability or action.

     This Power of Attorney supersedes any power of attorney previously executed
by the undersigned regarding the purposes outlined in the first paragraph hereof
("Prior Powers of Attorney"), and the authority of the attorneys-in-fact named
in any Prior Powers of Attorney is hereby revoked.

     This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 or 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier (a) revoked by the undersigned in a signed writing delivered to
the foregoing attorneys-in- fact or (b) superseded by a new power of attorney
regarding the purposes outlined in the first paragraph hereof dated as of a
later date.

     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 16th day of November, 2018.

                                            /s/ Vladimir Vexler
                                            ------------------------
                                            VLADIMIR VEXLER